cbdMD (YCBD) Gains from Investment Securities (2019 - 2024)
cbdMD (YCBD) posted Gains from Investment Securities of -$4828.0 for Q1 2024, up 93.08% sequentially from -$69752.0 in Q4 2023, and up 89.94% YoY from -$2541.8 in Q2 2023.
cbdMD (YCBD) Gains from Investment Securities (2019 - 2024) Analysis & Trends
cbdMD has reported Gains from Investment Securities for 6 years, with the latest figure at -$4828.0 in Q1 2024.
- Quarterly Gains from Investment Securities rose 89.94% year-over-year to -$4828.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was -$4828.0 (up 97.52% YoY) and the FY2024 annual result came in at -$74580.0, up 59.83% from the prior year.
- Gains from Investment Securities rose to -$4828.0 in Q1 2024 per YCBD's latest filing, from -$69752.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $8.9 million in Q1 2021 and troughed at -$21.3 million in Q1 2020.
- A 5-year average of -$1.6 million and a median of -$69752.0 in 2023 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2020 and 2021: Gains from Investment Securities soared 150.3% in 2020, then plunged 170.0% in 2021.
- Over 5 years, Gains from Investment Securities stood at $8.5 million in 2020, then slumped by 170.0% to -$5.9 million in 2021, then jumped by 98.97% to -$61000.0 in 2022, then declined by 14.35% to -$69752.0 in 2023, then jumped by 93.08% to -$4828.0 in 2024.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$4828.0, -$69752.0, and -$31867.0 for Q1 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -4,828.00 |
| Mar 31, 2024 | -4,828.00 |
| Dec 31, 2023 | -69,752.00 |
| Dec 31, 2023 | -69,752.00 |
| Sep 30, 2023 | -31,867.00 |
| Sep 30, 2023 | -31,867.00 |
| Jun 30, 2023 | -44,771.00 |
| Jun 30, 2023 | -44,771.00 |
| Mar 31, 2023 | -48,000.00 |
| Mar 31, 2023 | -48,000.00 |
| Dec 31, 2022 | -61,000.00 |
| Dec 31, 2022 | -61,000.00 |
| Sep 30, 2022 | -227,999.00 |
| Sep 30, 2022 | -227,999.00 |
| Jun 30, 2022 | -1.94 Mn |
| Jun 30, 2022 | -1.94 Mn |
| Mar 31, 2022 | -353,000.00 |
| Mar 31, 2022 | -353,000.00 |
| Dec 31, 2021 | -5.95 Mn |
| Dec 31, 2021 | -5.95 Mn |